Company Overview and News
The following slide deck was published by China Life Insurance Company Limited in conjunction with their 2018 Q1 earnings call.
Chicago, IL – May 11, 2018 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
Stocks sold off handily on Tuesday as the 3% mark on the 10-year Treasury yield was challenged, but stocks were trying to stage a small rally on Wednesday morning. Some investors have reconsidered what the nine-year bull market may bring in 2018 and beyond. It has become clear that the multiyear trend of buying pullbacks is now more vulnerable to sellers, volatility and each major news headline. Many investors are finding it harder to decide how they want their assets positioned for the longer term.
Chicago, IL – April 19, 2018 – Today, Zacks Equity Research discusses the Industry: Insurance, Part 2, including FGL Holdings (FG - Free Report) , Health Insurance Innovations, Inc. (HIIQ - Free Report) and China Life Insurance Company Limited (LFC - Free Report) .
The rate environment has been favoring life insurers since the Fed started tightening its monetary policy a couple of years back, given the high sensitivity of their business models to interest rates. But neither the pace nor the magnitude of rate hikes has been enough for a measurable benefit so far.
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
The following slide deck was published by China Life Insurance Company Limited in conjunction with this event.
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
The following slide deck was published by China Life Insurance Company Limited in conjunction with their 2017 Q4 earnings call.
China Life Insurance Co. Ltd’s (LFC - Free Report) ) net profit attributable to equity holders was $5.1 billion (RMB 32.2 billion) at the end of 2017, reflecting 68.6% year-over-year growth. The upside was primarily driven by higher revenues.
China Life Insurance Co. Ltd (LFC - Free Report) continues to benefit from revenue growth backed by surging level of premiums, especially in its Life Insurance business.
When investors hear that one of the world’s top credit ratings agencies has issued a sovereign downgrade of one of the world’s biggest nations, it tends to bring more than just some attention. On Thursday, Standard & Poor’s issued a sovereign credit rating downgrade for China. The issues behind the downgrade may look harsh or sound as though they are a large concern. There may be a problem with assuming the worst — China is similar to the United States in that the nation has endless means to meet its obligations, and the phrase “we have seen this movie before” should come to mind.
My Ian's Million Fund, IMF, is a quasi-index fund where I have two main goals. One, beat the S&P 500 over time with my own diversified basket of stocks, while avoiding any ongoing management fees. Two, build a model that my non-investment professional friends can copy. If I didn't have other investments and had $1,000/month to invest, what retirement portfolio would I build to ensure I ended up with a strong solid nest egg? The IMF answers that question.
The biggest economic and financial market story for Wednesday should be that Moody’s has formally downgraded China’s credit rating. Although this downgrade may sound harsh, the new “stable” outlook seems to mean that the balance of risk and upside are now adequately reflected in the larger global macroeconomic picture. Perhaps the biggest news should really be why Chinese and other markets did not have severe reactions to the downgrade.
12h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
12h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
22h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...